Royal Philips Reports Increase in 2Q Sales, Comparable-Sales Growth

Dow Jones

Jul 28

Royal Philips reported increased sales in its second quarter, driven by growth across all its business segments.

The Dutch health-technology company reported group sales of 4.4 billion euros ($5 billion), reflecting comparable-sales growth of 4%. Analysts polled by FactSet expected EUR4.31 billion.

Income from operations was EUR609 million. Adjusted earnings before interest, taxes, depreciation and amortization increased about 16%.

The company said comparable order intake declined 1% with growth in diagnosis & treatment offset by the shifting timing of large connected-care orders.

Chief Executive Roy Jakobs said customer demand for the company's products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth.

He added that Philips largely completed its U.S. tariff-refund process, and its productivity program is on track to helping offset macroeconomic pressures.

For the fiscal year, Philips continues to guide for comparable-sales growth between 3% and 4.5% and adjusted EBITA margin between 13.5% and 14%.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 27, 2026 15:30 ET (19:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2654271047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654271047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654271047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654271047","market":"us","top_or_hot":-1,"title":"Royal Philips Reports Increase in 2Q Sales, Comparable-Sales Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Royal Philips reported increased sales in its second quarter, driven by growth across all its business segments. \n</p>\n<p>\n  The Dutch health-technology company reported group sales of 4.4 billion euros ($5 billion), reflecting comparable-sales growth of 4%. Analysts polled by FactSet expected EUR4.31 billion. \n</p>\n<p>\n  Income from operations was EUR609 million. Adjusted earnings before interest, taxes, depreciation and amortization increased about 16%. \n</p>\n<p>\n  The company said comparable order intake declined 1% with growth in diagnosis &amp; treatment offset by the shifting timing of large connected-care orders. \n</p>\n<p>\n  Chief Executive Roy Jakobs said customer demand for the company's products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth. \n</p>\n<p>\n  He added that Philips largely completed its U.S. tariff-refund process, and its productivity program is on track to helping offset macroeconomic pressures. \n</p>\n<p>\n  For the fiscal year, Philips continues to guide for comparable-sales growth between 3% and 4.5% and adjusted EBITA margin between 13.5% and 14%. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 15:30 ET (19:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Royal Philips Reports Increase in 2Q Sales, Comparable-Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoyal Philips Reports Increase in 2Q Sales, Comparable-Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 03:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Royal Philips reported increased sales in its second quarter, driven by growth across all its business segments. \n</p>\n<p>\n  The Dutch health-technology company reported group sales of 4.4 billion euros ($5 billion), reflecting comparable-sales growth of 4%. Analysts polled by FactSet expected EUR4.31 billion. \n</p>\n<p>\n  Income from operations was EUR609 million. Adjusted earnings before interest, taxes, depreciation and amortization increased about 16%. \n</p>\n<p>\n  The company said comparable order intake declined 1% with growth in diagnosis &amp; treatment offset by the shifting timing of large connected-care orders. \n</p>\n<p>\n  Chief Executive Roy Jakobs said customer demand for the company's products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth. \n</p>\n<p>\n  He added that Philips largely completed its U.S. tariff-refund process, and its productivity program is on track to helping offset macroeconomic pressures. \n</p>\n<p>\n  For the fiscal year, Philips continues to guide for comparable-sales growth between 3% and 4.5% and adjusted EBITA margin between 13.5% and 14%. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 15:30 ET (19:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGLD","symbol_name":"皇家黄金","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654271047","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654271047","pubTimestamp":1785180600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Royal Philips reported increased sales in its second quarter, driven by growth across all its business segments.The Dutch health-technology company reported group sales of 4.4 billion euros , reflecting comparable-sales growth of 4%. Analysts polled by FactSet expected EUR4.31 billion.Income from operations was EUR609 million. Adjusted earnings before interest, taxes, depreciation and amortization increased about 16%.The company said comparable order intake declined 1% with growth in diagnosis & treatment offset by the shifting timing of large connected-care orders.Chief Executive Roy Jakobs said customer demand for the company's products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth.He added that Philips largely completed its U.S. tariff-refund process, and its productivity program is on track to helping offset macroeconomic pressures.For the fiscal year, Philips continues to guide for comparable-","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RGLD":"皇家黄金"},"translate_title":"皇家飞利浦报告第二季度销售额增长，可比销售额增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLD":1.5},"content_text":"Royal Philips reported increased sales in its second quarter, driven by growth across all its business segments. \n\n\n  The Dutch health-technology company reported group sales of 4.4 billion euros ($5 billion), reflecting comparable-sales growth of 4%. Analysts polled by FactSet expected EUR4.31 billion. \n\n\n  Income from operations was EUR609 million. Adjusted earnings before interest, taxes, depreciation and amortization increased about 16%. \n\n\n  The company said comparable order intake declined 1% with growth in diagnosis & treatment offset by the shifting timing of large connected-care orders. \n\n\n  Chief Executive Roy Jakobs said customer demand for the company's products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth. \n\n\n  He added that Philips largely completed its U.S. tariff-refund process, and its productivity program is on track to helping offset macroeconomic pressures. \n\n\n  For the fiscal year, Philips continues to guide for comparable-sales growth between 3% and 4.5% and adjusted EBITA margin between 13.5% and 14%. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 27, 2026 15:30 ET (19:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}